Pralsetinib (BLU-667)
Names
[ CAS No. ]:
2097132-94-8
[ Name ]:
Pralsetinib (BLU-667)
Biological Activity
[Description]:
Blu667 is a highly potent and selective RET inhibitor with an IC50 of 0.4 nM for wild type RET kinase.
[Related Catalog]:
[Target]
IC50: 0.12 nM (Wild type RET)[2]
[In Vitro]
Blu667 is a RET inhibitor extracted from patent US20170121312A1, compound example 129[1]. BLU-667 demonstrates more than 10-fold increased potency over approved MKIs against oncogenic RET variants and resistance mutants. BLU-667 demonstrates potent activity (IC50=0.4 nM) against common oncogenic RET alterations, including RET M918T, an activating mutation found in MTC, as well as the CCDC6-RET fusion observed in PTC and NSCLC. BLU-667 suppresses RET pathway signaling in a panel of RET-driven cell lines: LC2/ad (CCDC6-RET, NSCLC), MZ-CRC-1 (RET M918T, MTC), and TT (RET C634W, MTC)[2].
[In Vivo]
BLU-667 potently inhibits growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). BLU667 showed potent dose dependent activity against both KIF5B-RET Ba/F3 and KIF5B-RET V804L Ba/F3 allograft tumors with doses as low as 10 mg/kg twice-daily[2].
[Cell Assay]
KIF5B-RET Ba/F3 cells are exposed to compound concentrations ranging from 25 µM to 95.4 pM for 48 hours, and proliferation is assessed with Cell Titer Glo. TT, MZ-CRC-1, TPC-1 or LC2/ad cells are exposed to compound for 4 days and proliferation is measured by BrdU incorporation[2].
[Animal admin]
Mice[2] BALB/c nude mice are inoculated subcutaneously into the right flank with KIF5B-RET Ba/F3 cells, KIF5B-RET V804L Ba/F3 cells, or TT cells. For all experiments, mice are dosed twice-daily with vehicle, 3 mg/kg, 10 mg/kg, or 30 mg/kg BLU-667 or once-daily with 60 mg/kg BLU-667 or 60 mg/kg cabozantinib[2].
[References]
[Related Small Molecules]
Captisol
|
Cyclosporin A
|
H2DCFDA
|
0MPTP hydrochloride
|
GW4869
|
Etomoxir
|
TD139
|
Mitoquinone mesylate
|
GSK2795039
|
JC-1
|
BAPTA-AM
|
AP 20187
|
Setanaxib (GKT137831)
|
D-Luciferin
|
Crotaline
Chemical & Physical Properties
[ Molecular Formula ]:
C27H32FN9O2
[ Molecular Weight ]:
533.6